Palliative therapy for pancreatic/biliary cancer

Michael House, Michael A. Choti

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Palliative treatment for unresectable periampullary cancer is directed at three major symptoms: obstructive jaundice, duodenal obstruction, and cancer-related pain. In most cases, the pattern of symptoms at the time of diagnosis in the context of the patient's medical condition and projected survival influence the decision to perform an operative versus a nonoperative palliative procedure. Despite improvements in preoperative imaging and laparoscopic staging of patients with periampullary cancer and hilar cholangiocarcinoma, surgical exploration is the only modality that can definitively rule out resectability and the potential for curative resection in some patients with nonmetastatic cancer. Furthermore, only surgical management achieves successful palliation of obstructive symptoms and cancer-related pain as a single procedure during exploration. To take advantage of the long-term advantages afforded by surgical palliation, operative procedures must be performed with acceptable morbidity. The average postoperative length of hospital stay for patients who undergo surgical palliation is less than 15 days, even in those who develop minor complications. The average survival of patients who receive surgical palliation alone for nonmetastatic, unresectable pancreatic cancer is approximately 8 months. As with all treatment planning, palliative therapy for pancreatic and biliary cancer should be planned using a multidisciplinary approach, including input from the surgeon, gastroenterologist, radiologist, and medical and radiation oncologist. In this way, quality of life can be optimized in most patients with these diseases.

Original languageEnglish (US)
Pages (from-to)359-371
Number of pages13
JournalSurgical Clinics of North America
Volume85
Issue number2
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Biliary Tract Neoplasms
Pancreatic Neoplasms
Palliative Care
Length of Stay
Klatskin Tumor
Duodenal Neoplasms
Duodenal Obstruction
Neoplasms
Survival
Obstructive Jaundice
Operative Surgical Procedures
Quality of Life
Morbidity

ASJC Scopus subject areas

  • Surgery

Cite this

Palliative therapy for pancreatic/biliary cancer. / House, Michael; Choti, Michael A.

In: Surgical Clinics of North America, Vol. 85, No. 2, 04.2005, p. 359-371.

Research output: Contribution to journalArticle

House, Michael ; Choti, Michael A. / Palliative therapy for pancreatic/biliary cancer. In: Surgical Clinics of North America. 2005 ; Vol. 85, No. 2. pp. 359-371.
@article{f13890f6b5fa4cc8b4e329109b581a1e,
title = "Palliative therapy for pancreatic/biliary cancer",
abstract = "Palliative treatment for unresectable periampullary cancer is directed at three major symptoms: obstructive jaundice, duodenal obstruction, and cancer-related pain. In most cases, the pattern of symptoms at the time of diagnosis in the context of the patient's medical condition and projected survival influence the decision to perform an operative versus a nonoperative palliative procedure. Despite improvements in preoperative imaging and laparoscopic staging of patients with periampullary cancer and hilar cholangiocarcinoma, surgical exploration is the only modality that can definitively rule out resectability and the potential for curative resection in some patients with nonmetastatic cancer. Furthermore, only surgical management achieves successful palliation of obstructive symptoms and cancer-related pain as a single procedure during exploration. To take advantage of the long-term advantages afforded by surgical palliation, operative procedures must be performed with acceptable morbidity. The average postoperative length of hospital stay for patients who undergo surgical palliation is less than 15 days, even in those who develop minor complications. The average survival of patients who receive surgical palliation alone for nonmetastatic, unresectable pancreatic cancer is approximately 8 months. As with all treatment planning, palliative therapy for pancreatic and biliary cancer should be planned using a multidisciplinary approach, including input from the surgeon, gastroenterologist, radiologist, and medical and radiation oncologist. In this way, quality of life can be optimized in most patients with these diseases.",
author = "Michael House and Choti, {Michael A.}",
year = "2005",
month = "4",
doi = "10.1016/j.suc.2005.01.022",
language = "English (US)",
volume = "85",
pages = "359--371",
journal = "Surgical Clinics of North America",
issn = "0039-6109",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Palliative therapy for pancreatic/biliary cancer

AU - House, Michael

AU - Choti, Michael A.

PY - 2005/4

Y1 - 2005/4

N2 - Palliative treatment for unresectable periampullary cancer is directed at three major symptoms: obstructive jaundice, duodenal obstruction, and cancer-related pain. In most cases, the pattern of symptoms at the time of diagnosis in the context of the patient's medical condition and projected survival influence the decision to perform an operative versus a nonoperative palliative procedure. Despite improvements in preoperative imaging and laparoscopic staging of patients with periampullary cancer and hilar cholangiocarcinoma, surgical exploration is the only modality that can definitively rule out resectability and the potential for curative resection in some patients with nonmetastatic cancer. Furthermore, only surgical management achieves successful palliation of obstructive symptoms and cancer-related pain as a single procedure during exploration. To take advantage of the long-term advantages afforded by surgical palliation, operative procedures must be performed with acceptable morbidity. The average postoperative length of hospital stay for patients who undergo surgical palliation is less than 15 days, even in those who develop minor complications. The average survival of patients who receive surgical palliation alone for nonmetastatic, unresectable pancreatic cancer is approximately 8 months. As with all treatment planning, palliative therapy for pancreatic and biliary cancer should be planned using a multidisciplinary approach, including input from the surgeon, gastroenterologist, radiologist, and medical and radiation oncologist. In this way, quality of life can be optimized in most patients with these diseases.

AB - Palliative treatment for unresectable periampullary cancer is directed at three major symptoms: obstructive jaundice, duodenal obstruction, and cancer-related pain. In most cases, the pattern of symptoms at the time of diagnosis in the context of the patient's medical condition and projected survival influence the decision to perform an operative versus a nonoperative palliative procedure. Despite improvements in preoperative imaging and laparoscopic staging of patients with periampullary cancer and hilar cholangiocarcinoma, surgical exploration is the only modality that can definitively rule out resectability and the potential for curative resection in some patients with nonmetastatic cancer. Furthermore, only surgical management achieves successful palliation of obstructive symptoms and cancer-related pain as a single procedure during exploration. To take advantage of the long-term advantages afforded by surgical palliation, operative procedures must be performed with acceptable morbidity. The average postoperative length of hospital stay for patients who undergo surgical palliation is less than 15 days, even in those who develop minor complications. The average survival of patients who receive surgical palliation alone for nonmetastatic, unresectable pancreatic cancer is approximately 8 months. As with all treatment planning, palliative therapy for pancreatic and biliary cancer should be planned using a multidisciplinary approach, including input from the surgeon, gastroenterologist, radiologist, and medical and radiation oncologist. In this way, quality of life can be optimized in most patients with these diseases.

UR - http://www.scopus.com/inward/record.url?scp=17044383361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044383361&partnerID=8YFLogxK

U2 - 10.1016/j.suc.2005.01.022

DO - 10.1016/j.suc.2005.01.022

M3 - Article

VL - 85

SP - 359

EP - 371

JO - Surgical Clinics of North America

JF - Surgical Clinics of North America

SN - 0039-6109

IS - 2

ER -